About the Company
Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion. Bonney, a native of the Greater Boston area, graduated from Bates College before entering the pharmaceutical industry. He was hired by Biogen in 1995 eventually becoming the company's vice president for Sales and Marketing. During his tenure at the company he developed Avonex, which was according to MarketWatch, one of the most successful drugs in biotechnology history. He was appointed the chief operating officer of Cubist Pharmaceuticals in 2003 and served in the position for one year before becoming chief executive. His tenure as CEO saw mixed profit levels, criticism, and increased market volatility as well as the development and release of Cubicin, the most profitable launch of an antibiotic in the history of the United States. Bonney serves as an advisor to former Prime Minister David Cameron's Commission on Antimicrobial Resistance (AMR).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XFOR News
X4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62
The average one-year price target for X4 Pharmaceuticals (NasdaqCM:XFOR) has been revised to 3.62 / share. This is an ...
X4 Pharmaceuticals Inc (XFOR) Stock: A Guide to the Market Trend
Get insider insights on their strengths, past performance, and future potential. Make informed investment decisions and secure your future growth.
X4 Pharmaceuticals Inc (XFOR) Shares Soar Above 1-Year High
Based on X4 Pharmaceuticals Inc (XFOR), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -1.64. The debt to equity ratio ...
Bullish Or Bearish For X4 Pharmaceuticals Inc (NASDAQ: XFOR) In 2024
Data on historical trading for X4 Pharmaceuticals Inc (NASDAQ:XFOR) indicates that the trading volumes over the past 10 days have averaged 5.36 million and over the past 3 months, they’ve averaged ...
Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day
All day - It is the five-year anniversary of the Beyond Meat ( BYND) IPO. The IPO was priced at $25 per share, and the stock ...
N4 Pharma strikes partnership deal for intracellular delivery
(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc. N4 Pharma is a Derbyshire, England-based pharmaceutical company focused on ...
Sabrent announces new Rocket 5 M.2 NVMe Gen 5 SSD
Phison Max14um controller peaking at 14GB/s Sabrent has announced its latest flagship M.2 NVMe SSD, the Rocket 5. Pairing up ...
Are Investors Undervaluing Marks and Spencer Group plc (LON:MKS) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marks and Spencer Group fair value estimate is UK£4.00 ...
Loading the latest forecasts...